Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tert-Butanol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | HMGCR | P04035 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butanol SCHEMBL8169028 | 1.00 | — | — | |
| Tert-Butanol SCHEMBL6194876 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TSHRCA1CA2CA9 | |
| Tert-Butanol SCHEMBL28305217 | 0.95 | TSHR (0.57) | ALDH1A1TSHRCA1CA2CA9 | |
| Tert-Butanol SCHEMBL27435481 | 0.95 | ALDH1A1 (0.57) | ALDH1A1TSHRCA1CA2CA9 | |
| Bicarbonate SCHEMBL28154408 | 0.90 | — | — | |
| Tert-Butanol SCHEMBL6273948 | 0.86 | — | — | |
| Bicarbonate SCHEMBL9577103 | 0.86 | ALDH1A1 (0.57) | ALDH1A1TSHRCA1CA2CA9 | |
| Bicarbonate SCHEMBL9790007 | 0.84 | CA1 (0.56) | ALDH1A1TSHRCA1CA2CA9 | |
| Bicarbonate SCHEMBL8577664 | 0.84 | — | — | |
| Tert-Butanol SCHEMBL4348456 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | claimed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | claimed |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-13 | — | — | US | claimed |
| EP-2857401-B1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | MEIJI SEIKA PHARMA CO LTD (JP) | 2019-09-18 | — | — | EP | claimed |
| US-20180258089-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-09-13 | — | — | US | claimed |
| US-20170233393-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-08-17 | — | — | US | claimed |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-28 | — | — | US | claimed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | claimed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | claimed |
| US-7902190-B2 | Indol derivatives, the method for preparing thereof and composition for the prevention and treatment of metabolic disorder containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2011-03-08 | — | — | US | claimed |
| US-20100075962-A1 | INDOL DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND COMPOSITION FOR THE PREVENTION AND TREATMENT OF METABOLIC DISORDER CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-03-25 | — | — | US | claimed |
| EP-1068182-B1 | PROCESS FOR PREPARING A PROTECTED 4-AMINOMETHYL-PYRROLIDIN-3-ONE | LG LIFE SCIENCES LTD (KR) | 2005-06-08 | — | — | EP | claimed |
| US-20040014804-A1 | Methods for producing amino-substituted chromanes | ELI LILLY AND COMPANY | 2004-01-22 | — | — | US | claimed |
| EP-1286983-A2 | METHODS FOR PRODUCING AMINO-SUBSTITUTED CHROMANES | Eli Lilly & Company (US) | 2003-03-05 | — | — | EP | claimed |
| WO-2001094331-A2 | METHODS FOR PRODUCING AMINO-SUBSTITUTED CHROMANES | ELI LILLY & COMPANY (US) | 2001-12-13 | — | — | WO | claimed |
| US-6307059-B1 | PREPARATION OF QUINOLONE ANTIBIOTICS. | LG CHEMICAL, LTD (KR) | 2001-10-23 | — | — | US | claimed |
| EP-1068182-A1 | PROCESS FOR PREPARING A PROTECTED 4-AMINOMETHYL-PYRROLIDIN-3-ONE | LG Life Sciences Ltd. (KR) | 2001-01-17 | — | — | EP | claimed |
| WO-1999044991-A1 | PROCESS FOR PREPARING A PROTECTED 4-AMINOMETHYL-PYRROLIDIN-3-ONE | LG CHEMICAL LTD. (KR) | 1999-09-10 | — | — | WO | claimed |
| US-11998560-B2 | Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against multidrug and extensively drug-resistant Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates | UNIVERSITY OF MANITOBA (CA) | 2024-06-04 | — | — | US | disclosed |
| EP-0173441-A1 | Amino acid derivatives having anti-tumor activity and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1986-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | ALDH1A1 1362/4885TSHR 1888/4885CA1 3604/4885 |
| US-20100075962-A1 | INDOL DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND COMPOSITION FOR THE PREVENTION AND TREATMENT OF METABOLIC DISORDER CONTAINING THE SAME AS AN ACTIVE INGREDIENT | DGAT2, DGAT1, SOAT2 | ALDH1A1 908/4885TSHR 2666/4885CA1 4371/4885 |
| US-20040014804-A1 | Methods for producing amino-substituted chromanes | PFKP, TBXAS1, TBXA2R | ALDH1A1 899/4885TSHR 2589/4885CA1 1309/4885 |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, MRPL21, FNTB | ALDH1A1 502/4885TSHR 1913/4885CA1 1822/4885 |
| US-11998560-B2 | Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against multidrug and extensively drug-resistant Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates | MGAM, COASY, ABCC1 | ALDH1A1 2492/4885TSHR 2797/4885CA1 4252/4885 |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, FN1, FNTB | ALDH1A1 466/4885TSHR 1719/4885CA1 2224/4885 |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | ALDH1A1 1362/4885TSHR 1888/4885CA1 3604/4885 |
| US-20180258089-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | ALDH1A1 1362/4885TSHR 1888/4885CA1 3604/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | ALDH1A1 1362/4885TSHR 1888/4885CA1 3604/4885 |
| US-20170233393-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | FN1, FNTB, CPN1 | ALDH1A1 495/4885TSHR 3303/4885CA1 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.